Global Nuclear Medicine/Radiopharmaceutic Market By Type (Diagnostic Radioisotopes , and Therapeutic Radioisotopes), By Application (Oncology , and Cardiology), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- account_circleAbout Me
- 51481
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
Global Nuclear Medicine/Radiopharmaceutic Market is estimated to be valued US$ XX.X million in 2019. The report on Nuclear Medicine/Radiopharmaceutic Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global nuclear medicine/radiopharmaceutic market is segmented on the basis of type, application, and geography.
Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.
Nuclear Medicine/Radiopharmaceutic Market Scope:
By type, the market is segmented into Diagnostic Radioisotopes, and Therapeutic Radioisotopes. By application, the market is divided into Oncology, and Cardiology.
Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Company, Bracco Imaging, Bayer, Mallinckrodt, Nordion, Triad Isotopes, Lantheus, IBA Group, GE Healthcare, China Isotope & Radiation, Jubilant Pharma, Eli Lilly, Advanced Accelerator Applications, SIEMENS, Dongcheng, and Navidea.
Key Market Segments
Type
- Diagnostic Radioisotopes
- Therapeutic Radioisotopes
Application
- Oncology
- Cardiology
Key Market Players included in the report:
- Company
- Bracco Imaging
- Bayer
- Mallinckrodt
- Nordion
- Triad Isotopes
- Lantheus
- IBA Group
- GE Healthcare
- China Isotope & Radiation
- Jubilant Pharma
- Eli Lilly
- Advanced Accelerator Applications
- SIEMENS
- Dongcheng
- Navidea
Reasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis - industry research (global industry trends) and Nuclear Medicine/Radiopharmaceutic Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Nuclear Medicine/Radiopharmaceutic Market; high-growth regions; and market drivers, restraints, and also market chances.
The analysis covers Nuclear Medicine/Radiopharmaceutic Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Nuclear Medicine/Radiopharmaceutic Market across sections such as also application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Nuclear Medicine/Radiopharmaceutic Market together side their company profiles, SWOT analysis, latest advancements, and business plans.
The analysis objectives of the report are:
- To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
- To know the Nuclear Medicine/Radiopharmaceutic Market by pinpointing its many subsegments.
- To profile the important players and analyze their growth plans.
- To endeavor the amount and value of Nuclear Medicine/Radiopharmaceutic sub-markets, depending on key regions (various vital states).
- To analyze Nuclear Medicine/Radiopharmaceutic Market concerning growth trends, prospects, and also their participation in the entire sector.
- To examine and study the Nuclear Medicine/Radiopharmaceutic Market size (volume & value) from the company, essential regions/countries, products, and application, background information from 2013 to 2018, and also prediction to 2029.
- Primary worldwide Nuclear Medicine/Radiopharmaceutic Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
- To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.
For the Nuclear Medicine/Radiopharmaceutic Market research study, the following years have been considered to estimate the market size:
Particular Scope Region - North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Historic Year 2016 to 2020 Base Year 2021 Estimated Year 2022 Forecast Year 2023 to 2032 - account_circleAbout Me
- 51481
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- 1. Nuclear Medicine/Radiopharmaceutic Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Nuclear Medicine/Radiopharmaceutic Market Overview
- 3.1. Nuclear Medicine/Radiopharmaceutic Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Production Analysis by Region/Company
- 3.9. Industry chain Analysis
- 3.10. Marketing Strategy
- 3.1. Nuclear Medicine/Radiopharmaceutic Market Dynamics
- 4. Global Nuclear Medicine/Radiopharmaceutic Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Nuclear Medicine/Radiopharmaceutic Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Diagnostic Radioisotopes
- 4.4. Therapeutic Radioisotopes
- 5. Global Nuclear Medicine/Radiopharmaceutic Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Nuclear Medicine/Radiopharmaceutic Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Oncology
- 5.4. Cardiology
- 6. Global Nuclear Medicine/Radiopharmaceutic Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia-Pacific
- 6.3.1. Asia-Pacific Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Nuclear Medicine/Radiopharmaceutic Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Nuclear Medicine/Radiopharmaceutic Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Company
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Bracco Imaging
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Bayer
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Mallinckrodt
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Nordion
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Triad Isotopes
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Lantheus
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. IBA Group
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. GE Healthcare
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. China Isotope & Radiation
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Jubilant Pharma
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. Eli Lilly
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. Advanced Accelerator Applications
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 7.16. SIEMENS
- 7.16.1. Company Overview
- 7.16.2. Financial Highlights
- 7.16.3. Product Portfolio
- 7.16.4. SWOT Analysis
- 7.16.5. Key Strategies and Developments
- 7.17. Dongcheng
- 7.17.1. Company Overview
- 7.17.2. Financial Highlights
- 7.17.3. Product Portfolio
- 7.17.4. SWOT Analysis
- 7.17.5. Key Strategies and Developments
- 7.18. Navidea
- 7.18.1. Company Overview
- 7.18.2. Financial Highlights
- 7.18.3. Product Portfolio
- 7.18.4. SWOT Analysis
- 7.18.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- ondemand_videoVideos
- 51481
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- Company
- Bracco Imaging
- Bayer
- Mallinckrodt
- Nordion
- Triad Isotopes
- Lantheus
- IBA Group
- GE Healthcare
- China Isotope & Radiation
- Jubilant Pharma
- Eli Lilly
- Advanced Accelerator Applications
- SIEMENS
- Dongcheng
- Navidea
- settingsSettings